期刊
CLINICAL IMMUNOLOGY
卷 153, 期 1, 页码 187-198出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2014.04.014
关键词
Anti-CTLA-4; Anti-Glut2; Dendritic cells; Regulatory T cells; Diabetes; Tolerance
类别
资金
- National Institutes of Health [1R41AI085677-01]
- Tolerogenics, a startup biotech company in Illinois
To prepare a novel Bispecific Antibody (BsAb) as a potential targeted therapy for T1D, we produced a functionally inert monoclonal antibody (mAb) against Glucose transporter-2 (GLUT-2) expressed on beta-cells to serve as an anchoring antibody. The therapeutic am is. an agonistic mAb against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), a negative regulator of T-cell activation expressed on activated CD4+ T-cells. A BsAb was prepared by chemically coupling an anti-GLUT2 mAb to an agonistic anti-CTLA-4 mAb. This BsAb was able to bind to GLUT2 and CTLA-4 in vitro, and to pancreatic islets, both in vitro and in vivo. We tested the safety and efficacy of this BsAb by treating Non-Obese Diabetes (NOD) mice and found that it could delay the onset of diabetes with no apparent undesirable side effects. Thus, engagement of CTLA-4 on activated T cells from target tissue can be an effective way to treat type-1 diabetes. (C) 2014 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据